Tempest Therapeutics Inc. Common Stock TPST · Stock Open Tempest Therapeutics Inc. Common Stock in new tab
Tempest Therapeutics Inc. Common Stock Analysis (TPST)
Is Tempest Therapeutics Inc. Common Stock a good investment? Tempest Therapeutics Inc. Common Stock (TPST) is currently trading at 1.21 USD.
Earnings Schedule: Tempest Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is -1.21.
Investor FAQ
Does Tempest Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tempest Therapeutics Inc. Common Stock?
Tempest Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of -5.70.
Company Profile
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Dec. 10, 2018 | 0.070000 |
| June 28, 2021 | 0.070000 |
| April 9, 2025 | 0.080000 |
Community Discussion